


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-9 (Cancelled).

10. (Currently Amended) A method for preventing/ameliorating diabetic maculopathy in a mammal comprising administering to the subject an effective amount of a compound represented by the following general formula:



wherein X represents a halogen or a hydrogen atom, R<sup>1</sup> and R<sup>2</sup> concurrently or differently represent a hydrogen atom or ~~an optionally substituted~~ a C1 to C6 alkyl group, or R<sup>1</sup> and R<sup>2</sup>, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle.

11. (Previously Presented) The method for preventing/ameliorating diabetic maculopathy according to claim 10, wherein the compound is administered in the form of an oral agent.

12. (Previously Presented) The method for preventing/ameliorating diabetic maculopathy according to claim 10, wherein the compound is (2S, 4S)-6-fluoro-2',5'-dioxospiro [chroman-4,4'-imidazolidine]-2-carboxamide.

13. (Currently Amended) The method for preventing/ameliorating diabetic maculopathy according to claim 10, which is [[used]] for use in treating macular edema or retinal pigment epitheliopathy in diabetic maculopathy. |

14. (Currently Amended) The method for preventing/ameliorating diabetic maculopathy according to claim 10, which is [[used]] for use in improving visual acuity or inhibiting a deterioration of visual acuity in diabetic maculopathy. |

Claims 15-17 (Cancelled).